Breaking News Instant updates and real-time market news.

SRPT

Sarepta

$37.89

6.63 (21.21%)

09:03
01/11/17
01/11
09:03
01/11/17
09:03

Sarepta Exondys 51 off to 'solid start,' says JMP Securities

After Sarepta reported that it had obtained revenue of more than $5M from its Exondys 51 drug, JMP Securities analyst Liisa Bayko says that the drug is off to a "solid start." The analyst expects the drug to be launched in the EU in 2019 and continues to recommend the stock.

SRPT Sarepta
$37.89

6.63 (21.21%)

01/10/17
BARD
01/10/17
NO CHANGE
Target $102
BARD
Outperform
Baird expects Sarepta 'relief rally' on launch update
Baird analyst Brian Skorney expects a "relief rally" in shares of Sarepta Therapeutics after the company announced Exondys 51 sales of $5.4M and greater than 250 patient start forms were submitted by year-end. If the shares were at $60, the sales figure would be a disappointment, but expectations have been lowered and whisper numbers were nearing negative territory, Skorney tells investors in a research note following Sarepta's JPMorgan Conference presentation. "This is just the beginning," as the company has dystrophin data coming from SRP-4053 in exon-53-amenable patients in the first half of 2017 and data plans to advance at least three additional assets, the analyst contends. Skorney keeps an Outperform rating on Sarepta with a $102 price target.
01/10/17
LEER
01/10/17
NO CHANGE
LEER
Market Perform
Leerink discusses discrepancy between Sarepta revenue, start forms
Leerink analyst Joseph Schwartz says that for Sarepta Therapeutics to meet the Q4 revenue estimate of $6.0M, he anticipated a greater than 200 start form number. The company, however, reported $5.4M in sales despite a start form number of over 250. The discrepancy between start forms and the revenue miss could be due to several factors, including the translatability of start forms to reimbursed written prescriptions and patient demographics, Schwartz tells investors in a research note. Continued push-back from payors that limit reimbursement could render the start form number inaccurate, he contends. The analyst views today's numbers from Sarepta as "encouraging," but sees room for improvement. Schwartz keeps a Market Perform rating on the shares.
01/10/17
PIPR
01/10/17
NO CHANGE
Target $68
PIPR
Overweight
Piper says Sarepta Q4 sales topped estimate
Piper Jaffray analyst Edward Tenthoff says Sarepta Therapeutics' Q4 Exondys 51 sales of $5.4M beat his estimate of $4.5M. The company is making good progress on reimbursement and expects payor conversions to accelerate in Q2, Tenthoff tells investors in a research note. He estimates U.S. Exondys 51 sales of $274M in 2017 with peak U.S. sales of greater than $500M. Tenthoff reiterates an Overweight rating on Sarepta with a $68 price target.
01/11/17
RBCM
01/11/17
NO CHANGE
RBCM
Sarepta EXONDYS 51 launch encouraging, says RBC Capital
RBC Capital analyst Simos Simeonidis notes that Sarepta reported that it only obtained revenue of $5.4M from its EXONDYS 51 in the wake of its launch. However, the analyst is "encouraged by the disclosure that 250 forms have been filled out for patients whose mutation status has been verified" as of the end of last year. Simeonidis continues to predict that the drug will undergo a "slow and gradual ramp," with its sales accelerating significantly in the "later" quarters of this year. The analyst keeps a $98 price target and an Outperform rating on the stock.

TODAY'S FREE FLY STORIES

02:30
01/19/18
01/19
02:30
01/19/18
02:30
General news
FX Update: The dollar has traded softer on U.S. political concerns »

FX Update: The dollar…

01:50
01/19/18
01/19
01:50
01/19/18
01:50
General news
FX Action: USD-JPY has traded moderately softer »

FX Action: USD-JPY has…

COLD

Americold Realty Trust

20:35
01/18/18
01/18
20:35
01/18/18
20:35
Syndicate
Americold Realty Trust 45.3M share IPO priced at $16.00 »

The company sold 29M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

HTGM

HTG Molecular

$3.40

0.54 (18.88%)

20:29
01/18/18
01/18
20:29
01/18/18
20:29
Syndicate
HTG Molecular 12M share Secondary priced at $2.90 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

NINE

Nine Energy Services

20:27
01/18/18
01/18
20:27
01/18/18
20:27
Syndicate
Nine Energy Services 7M share IPO priced at $23.00 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

SLB

Schlumberger

$76.37

-0.84 (-1.09%)

, STI

SunTrust

$67.94

-0.41 (-0.60%)

20:25
01/18/18
01/18
20:25
01/18/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

SLB

Schlumberger

$76.37

-0.84 (-1.09%)

STI

SunTrust

$67.94

-0.41 (-0.60%)

SYF

Synchrony

$37.30

-0.76 (-2.00%)

CFG

Citizens Financial

$45.76

-0.08 (-0.17%)

RF

Regions Financial

$18.15

-0.21 (-1.14%)

KSU

Kansas City Southern

$111.50

0.69 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 19

    Jan

  • 19

    Jan

  • 19

    Jan

  • 19

    Jan

  • 19

    Jan

  • 20

    Apr

  • 20

    Jul

  • 19

    Oct

URGN

UroGen Pharma

$42.46

-0.8 (-1.85%)

19:12
01/18/18
01/18
19:12
01/18/18
19:12
Syndicate
UroGen Pharma 1.463M share Secondary priced at $41.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

ADT

ADT Inc.

19:10
01/18/18
01/18
19:10
01/18/18
19:10
Syndicate
ADT Inc. 105M share IPO priced at $17.00-19.00 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

SPX

S&P 500

, SPY

SPDR S&P 500 ETF Trust

$279.14

-0.47 (-0.17%)

18:47
01/18/18
01/18
18:47
01/18/18
18:47
Periodicals
House Freedom Caucus to support bill preventing government shutdown, AP says 

Reference Link

SPX

S&P 500

SPY

SPDR S&P 500 ETF Trust

$279.14

-0.47 (-0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BK

BNY Mellon

$55.35

-2.54 (-4.39%)

18:39
01/18/18
01/18
18:39
01/18/18
18:39
Periodicals
BNY Mellon to boost wages for 1,000 workers after tax reform, WSJ says »

Bank of New York Mellon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 08

    Mar

TRNC

tronc

$19.23

0.22 (1.16%)

18:28
01/18/18
01/18
18:28
01/18/18
18:28
Periodicals
tronc to investigate LA Times' CEO Ross Levinsohn, Financial Times reports »

tronc has opened an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

IBM

IBM

$169.12

0.47 (0.28%)

18:19
01/18/18
01/18
18:19
01/18/18
18:19
Hot Stocks
IBM's Schroeter says mainframe isn't going away »

IBM senior VP of Global…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

ATR

AptarGroup

$87.24

0.4 (0.46%)

18:16
01/18/18
01/18
18:16
01/18/18
18:16
Hot Stocks
AptarGroup chairman King Harris to retire in May »

AptarGroup chairman of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

  • 27

    Apr

  • 02

    May

  • 27

    Jul

  • 26

    Oct

FULT

Fulton Financial

$18.30

-0.25 (-1.35%)

18:12
01/18/18
01/18
18:12
01/18/18
18:12
Hot Stocks
Fulton Financial to raise its minimum wage to $12 per hour »

Fulton Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

SNAP

Snap

$14.01

0.49 (3.62%)

18:03
01/18/18
01/18
18:03
01/18/18
18:03
Periodicals
Snap fires roughly two dozen employees, Cheddar reports »

Snap Inc. has laid off…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 23

    Jan

  • 06

    Feb

  • 07

    Feb

PAVM

PAVmed

$2.54

-0.02 (-0.78%)

17:57
01/18/18
01/18
17:57
01/18/18
17:57
Syndicate
PAVmed files to sell common stock, no amount given »

Dawson James Securities…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PODD

Insulet

$72.89

-0.02 (-0.03%)

, DXCM

Dexcom

$56.28

-0.04 (-0.07%)

17:51
01/18/18
01/18
17:51
01/18/18
17:51
Recommendations
Insulet, Dexcom, TNDM, Medtronic analyst commentary at Piper Jaffray »

Insulet is a favored…

PODD

Insulet

$72.89

-0.02 (-0.03%)

DXCM

Dexcom

$56.28

-0.04 (-0.07%)

TNDM

TNDM

MDT

Medtronic

$87.26

1.15 (1.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 27

    Feb

  • 01

    Mar

17:50
01/18/18
01/18
17:50
01/18/18
17:50
General news
Breaking General news story  »

Cleveland Federal Reserve…

IBM

IBM

$169.12

0.47 (0.28%)

17:39
01/18/18
01/18
17:39
01/18/18
17:39
Earnings
Breaking Earnings news story on IBM »

IBM sees FY18 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

TTD

Trade Desk

$48.36

-1.12 (-2.26%)

17:38
01/18/18
01/18
17:38
01/18/18
17:38
Initiation
Trade Desk initiated at Stifel »

Trade Desk initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

$24.04

-0.52 (-2.12%)

, FB

Facebook

$179.80

2.2 (1.24%)

17:37
01/18/18
01/18
17:37
01/18/18
17:37
Hot Stocks
Snap user metrics being put into question by Mashable, Muddy Waters »

After the close, Mashable…

TWTR

Twitter

$24.04

-0.52 (-2.12%)

FB

Facebook

$179.80

2.2 (1.24%)

SNAP

Snap

$14.01

0.49 (3.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

  • 23

    Jan

  • 31

    Jan

  • 06

    Feb

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

TWTR

Twitter

$24.04

-0.52 (-2.12%)

17:37
01/18/18
01/18
17:37
01/18/18
17:37
Recommendations
Twitter analyst commentary at Stifel »

Twitter coverage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

IBM

IBM

$169.12

0.47 (0.28%)

17:36
01/18/18
01/18
17:36
01/18/18
17:36
Hot Stocks
Breaking Hot Stocks news story on IBM »

IBM sees FY18 free cash…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

IBM

IBM

$169.12

0.47 (0.28%)

17:36
01/18/18
01/18
17:36
01/18/18
17:36
Earnings
IBM sees Q1 EPS 17%-18% of $13.80 FY expectation, consensus $2.28 »

Says has momentum in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

ZG

Zillow

$43.86

-0.49 (-1.10%)

, Z

Zillow

$43.97

-0.57 (-1.28%)

17:33
01/18/18
01/18
17:33
01/18/18
17:33
Downgrade
Zillow, Zillow rating change at Stifel »

Zillow resumed with a…

ZG

Zillow

$43.86

-0.49 (-1.10%)

Z

Zillow

$43.97

-0.57 (-1.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.